Homeopathic Regulation Critics Will Swing For Change Against Industry Stalwarts At FDA Hearing
This article was originally published in The Tan Sheet
Executive Summary
In addition to marketers and trade groups, Gary Yingling, a former FDA counsel involved in the agency’s decision to omit homeopathics from the OTC drug review, will make a presentation at a public hearing April 20-21. FDA’s current approach as “a rational framework,” CHPA says.